Biogen Stock News

Sage Therapeutics (SAGE) and partner Biogen (BIIB) announce positive data from a cohort of an ongoing phase III study, currently evaluating their investigational major depressive disorder drug zuranol

Neurological and neurodegenerative diseases affect a vast segment of the population worldwide and there is a significant demand for treatments for these conditions. Biogen (BIIB) has a strong portfolio of […] The post Biogen (BIIB) stock research summary | Q3 2021 first appeared on AlphaStreet .

Sage Therapeutics Inc (NASDAQ: SAGE ) and Biogen Inc (NASDAQ: BIIB ) have announced 12-month data for the cohort of patients (n=199) who received zuranolone 50 mg once for 14-days as their initial dose in the ongoing Phase 3 open-label SHORELINE Study. Related: Sage Therapeutics - Biogen''s Zuranolone Tops Placebo In Reducing Depressive Symptoms . The data showed that zuranolone was generally well-tolerated, with no new safety findings or trends identified in the long-term safety Full story available on Benzinga.com

Biogen Inc. (NASDAQ:BIIB)s stock price reached a new 52-week low on Monday . The stock traded as low as $238.26 and last traded at $238.96, with a volume of 29443 shares. The stock had previously closed at $242.90. Several analysts have recently weighed in on the company. Bank of America reduced their price target on []

Sage Therapeutics, Inc. (Nasdaq: SAGE), and Biogen Inc. (Nasdaq: BIIB) today announced 12-month data for the cohort of patients (n=199), who received

Sage Therapeutics Inc (NASDAQ: SAGE) and Biogen Inc (NASDAQ: BIIB) have announced 12-month data for the cohort of patients (n=199) who received zuranolone 50 mg once for 14-days as their initial

On Tuesday, Biogen Inc. (NASDAQ:BIIB) shares fell slightly, extending the current monthly declines closer to 14%. The biotechnology company lost an appeal on its multiple sclerosis drug, Tecfidera, with the US Court of Appeals for the Federal Circuits upholding the decision made by a trial court. Biogen shares are also experiencing pressure from another report [] The post Is it too late to sell Biogen stock after losing an appeal on its multiple sclerosis drug? appeared first on Invezz.

On Tuesday, Biogen Inc. (NASDAQ:BIIB) shares fell slightly, extending the current monthly declines closer to 14%. The biotechnology company lost an appeal on its multiple sclerosis drug, Tecfidera, wi

Biogen Inc (NASDAQ: BIIB) lost its appeals court bid to revive a key patent on the blockbuster multiple sclerosis drug Tecfidera, reports Bloomberg. In a related ruling, the court also affirmed a de

Biogen Inc (BIIB) shares closed today at 0.4% above its 52 week low of $235.18, giving the company a market cap of $34B. The stock is currently down 3.6% year-to-date, down 3.1% over the past 12 months, and down 15.3% over the past five years. This week, the Dow Jones Industrial Average fell 1.4%, and the S&P 500 fell 0.6%. Trading Activity Trading volume this week was 15.0% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.3. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -140.2% The company's stock price performance over the past 12 months lags the peer average by -123.9% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is 14.8% higher than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Taylor Cottrill Erickson & Associates Inc. boosted its position in shares of Biogen Inc. (NASDAQ:BIIB) by 14.5% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 744 shares of the biotechnology companys stock after buying an additional 94 shares during the period. Taylor Cottrill []

Private Advisor Group LLC lifted its stake in Biogen Inc. (NASDAQ:BIIB) by 445.4% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 42,461 shares of the biotechnology companys stock after purchasing an additional 34,676 shares during the period. Private Advisor []

Biogen Inc (BIIB) shares closed today at 1.9% above its 52 week low of $238.40, giving the company a market cap of $36B. The stock is currently up 2.2% year-to-date, up 3.5% over the past 12 months, and down 11.0% over the past five years. This week, the Dow Jones Industrial Average fell 1.9%, and the S&P 500 fell 2.1%. Trading Activity Trading volume this week was 48.3% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.3. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -75.6% The company's stock price performance over the past 12 months lags the peer average by -76.6% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is 22.4% higher than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Accurate market intelligence can be obtained with the help of SWOT analysis provided in the first class Parathyroid adenoma market report that aid businesses identify opportunities as well as both internal and external influences. With the wonderful secondary research expertise